{
    "pmid": "41429094",
    "title": "Advances in studying the role of SCARA5 in tumors.",
    "abstract": "Scavenger receptor class A member 5 (SCARA5), a type II transmembrane glycoprotein, initially drew attention due to its involvement in iron metabolism and immune defense. In recent years, its tumor-suppressive function has been gradually validated in a variety of malignant tumors. SCARA5 is localized to the chromosomal region 8p21.1, a site with a high frequency of loss of heterozygosity (LOH) in tumors. Additionally, the high methylation of CpG islands in the SCARA5 promoter region, regulation by transcription factors, and post-transcriptional silencing mediated by non-coding RNAs (ncRNAs) collectively result in a significant downregulation of SCARA5 expression in tumors such as liver cancer, breast cancer, and colorectal cancer. Functionally, SCARA5 exerts multiple tumor-suppressive effects, including inhibiting tumor cell proliferation, inducing apoptosis, blocking epithelial-mesenchymal transition (EMT), and enhancing ferroptosis sensitivity. It achieves these effects by interacting with molecules such as FAK and ferritin to regulate signaling pathways like PI3K/Akt and Wnt/Î²-catenin. Furthermore, the expression level of SCARA5 is closely associated with tumor stage, lymph node metastasis, and patient prognosis, indicating its potential as a marker for tumor diagnosis and prognosis. Gene therapy, the application of DNA methyltransferase inhibitors (DNMTi), and the development of small-molecule drugs based on its regulatory mechanisms also offer new directions for precision tumor therapy. This article systematically reviews the gene and protein structure of SCARA5, its tumor-related mechanisms of action, expression regulatory network, and clinical translational value. It also analyzes current research gaps to provide references for future in-depth exploration.",
    "disease": "colorectal cancer",
    "clean_text": "advances in studying the role of scara in tumors scavenger receptor class a member scara a type ii transmembrane glycoprotein initially drew attention due to its involvement in iron metabolism and immune defense in recent years its tumor suppressive function has been gradually validated in a variety of malignant tumors scara is localized to the chromosomal region p a site with a high frequency of loss of heterozygosity loh in tumors additionally the high methylation of cpg islands in the scara promoter region regulation by transcription factors and post transcriptional silencing mediated by non coding rnas ncrnas collectively result in a significant downregulation of scara expression in tumors such as liver cancer breast cancer and colorectal cancer functionally scara exerts multiple tumor suppressive effects including inhibiting tumor cell proliferation inducing apoptosis blocking epithelial mesenchymal transition emt and enhancing ferroptosis sensitivity it achieves these effects by interacting with molecules such as fak and ferritin to regulate signaling pathways like pi k akt and wnt catenin furthermore the expression level of scara is closely associated with tumor stage lymph node metastasis and patient prognosis indicating its potential as a marker for tumor diagnosis and prognosis gene therapy the application of dna methyltransferase inhibitors dnmti and the development of small molecule drugs based on its regulatory mechanisms also offer new directions for precision tumor therapy this article systematically reviews the gene and protein structure of scara its tumor related mechanisms of action expression regulatory network and clinical translational value it also analyzes current research gaps to provide references for future in depth exploration"
}